Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
POET-COPD: Tiotropium vs Salmeterol
NCT00563381Phase 4Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jan 2008
- Primary completion
- Apr 2010
- Modality
- Small Molecules
- Countries
- 25
01
Overview
Phase 4, randomised, double-blind trial of tiotropium in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Time to First Occurrence of (Moderate or Severe) COPD Exacerbation at 52 weeks. Started Jan 2008; status: completed.
02
Drugs
tiotropium
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT00563381.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00563381.